Literature DB >> 8206393

Biologically active recombinant human complement factor H: synthesis and secretion by the baculovirus system.

A K Sharma1, M K Pangburn.   

Abstract

A complete cDNA clone (4.3 kb) encoding human complement factor H (hCFH; 155 kDa) has been cloned into the pVL1393 baculovirus expression vector and transfected into Spodoptera frugiperda Sf9 insect cells. A biologically active (92 +/- 15%) 140-kDa protein was secreted into the medium with a yield of more than 5 mg/liter. This is the first report of synthesis of biologically active recombinant hCFH in a heterologous system.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8206393     DOI： 10.1016/0378-1119(94)90116-3

Source DB:  PubMed          Journal:  Gene        ISSN： 0378-1119            Impact factor:   3.688


  13 in total

1.  Mesenchymal stem cells are injured by complement after their contact with serum.

Authors:  Yan Li; Feng Lin
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

2.  Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.

Authors:  Stefan Michelfelder; Juliana Parsons; Lennard L Bohlender; Sebastian N W Hoernstein; Holger Niederkrüger; Andreas Busch; Nicola Krieghoff; Jonas Koch; Benjamin Fode; Andreas Schaaf; Thomas Frischmuth; Martin Pohl; Peter F Zipfel; Ralf Reski; Eva L Decker; Karsten Häffner
Journal:  J Am Soc Nephrol       Date:  2016-12-08       Impact factor: 10.121

3.  Localization by site-directed mutagenesis of the site in human complement factor H that binds to Streptococcus pyogenes M protein.

Authors:  A K Sharma; M K Pangburn
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

4.  Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis.

Authors:  A K Sharma; M K Pangburn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  Production of biologically active complement factor H in therapeutically useful quantities.

Authors:  Christoph Q Schmidt; Fern C Slingsby; Anna Richards; Paul N Barlow
Journal:  Protein Expr Purif       Date:  2010-12-10       Impact factor: 1.650

6.  Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.

Authors:  Isabell C Pechtl; David Kavanagh; Nicola McIntosh; Claire L Harris; Paul N Barlow
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

7.  A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae.

Authors:  S Ram; A K Sharma; S D Simpson; S Gulati; D P McQuillen; M K Pangburn; P A Rice
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

8.  Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice.

Authors:  Heather Kerr; Andrew P Herbert; Elisavet Makou; Dariusz Abramczyk; Talat H Malik; Hannah Lomax-Browne; Yi Yang; Isabel Y Pappworth; Harriet Denton; Anna Richards; Kevin J Marchbank; Matthew C Pickering; Paul N Barlow
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

9.  An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.

Authors:  Eva-Maria Nichols; Thomas D Barbour; Isabel Y Pappworth; Edwin K S Wong; Jeremy M Palmer; Neil S Sheerin; Matthew C Pickering; Kevin J Marchbank
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

10.  An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Authors:  Yi Yang; Harriet Denton; Owen R Davies; Kate Smith-Jackson; Heather Kerr; Andrew P Herbert; Paul N Barlow; Matthew C Pickering; Kevin J Marchbank
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.